Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment / Device Design & Manufacturing
wuxiapptec.com

See what CB Insights has to offer

Founded Year

2000

Stage

IPO - II | IPO

Total Raised

$1.521B

About WuXi AppTec

WuXi AppTec (SH: 603259) is a global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with operations in China and the United States. The company provides a broad and integrated portfolio of services throughout the drug R&D process. WuXi AppTecs's services are designed to help their worldwide customers shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions.

WuXi AppTec Headquarter Location

288 Fute Zhong Road Waigaoqiao Free Trade Zone

Shanghai, Shanghai, 200131,

China

+86 (21) 5046-1111

Latest WuXi AppTec News

Coherent Biopharma Partners with CDMO WuXi STA

Dec 3, 2021

Source: Reptile8488/Getty Images December 3, 2021 WuXi STA, a subsidiary of WuXi AppTec, and Coherent Biopharma, signed a strategic partnership agreement whereby WuXi STA will become the preferred CDMO partner. The company will provide Coherent Biopharma with integrated CMC services to accelerate its present and future drug candidates (small molecule, peptide, oligonucleotide, and complex chemical conjugate, etc. ), from API to drug product. This will include but not be limited to process development, manufacturing, analytical, and regulatory filing support. In recent years, Peptide Drug Conjugates (PDC) have attracted attention from increasing numbers of pharmaceutical companies due to advantages such as strong tumor permeation, good scalability, and relatively good pharmacokinetics, etc., according to WuXi officials. Coherent Biopharma is focusing on the R&D and commercialization of tumor-targeting ligand-mediated drugs and tumor markers. Based on its BEST™ (Bi-Engaging ligand-mediated Selective Targeting) technology platform, Coherent Biopharma reports that it has developed a diverse product pipeline with the PDC products, including CBP-1008 and CBP-1018. The two drugs are in clinical trials in the US. Meanwhile, multiple new drugs are in various R&D stages, ready for clinical development in a few years, notes a Coherent spokesperson. Based on a prior successful collaboration on CBP-1008, this strategic partnership between Coherent Biopharma and WuXi STA is expected to broaden the collaboration beyond CBP-1008. PDC drugs have broad applications, but their development faces many technical challenges, says Minzhang Chen, PhD, Co-CEO of WuXi AppTec and CEO of WuXi STA. WuXi STA’s peptide platform provides comprehensive CDMO services from drug discovery to commercial manufacturing, adds Chen, who points out that this vertically integrated peptide platform covers unnatural amino acids, conjugates, peptide APIs to drug products, coupled with analytical support and CMC writing services.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

WuXi AppTec Patents

WuXi AppTec has filed 1 patent.

The 3 most popular patent topics include:

  • Cell biology
  • Clusters of differentiation
  • Flow cytometry
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/13/2019

Immunology, Immune system, Clusters of differentiation, Cell biology, Flow cytometry

Application

Application Date

9/13/2019

Grant Date

Title

Related Topics

Immunology, Immune system, Clusters of differentiation, Cell biology, Flow cytometry

Status

Application

WuXi AppTec Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

WuXi AppTec Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.